Efficacy of I-125 Versus Non-I-125 Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice

Li Shuangxi; He Xuewen; Dang Lei; Xu Fangyu; Fang Jin; Li Fenqiang; Wang Wenhui

首页> 外文期刊>Digestive Diseases and Sciences >Efficacy of I-125 Versus Non-I-125 Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice

【24h】

Efficacy of I-125 Versus Non-I-125 Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice

机译：I-125对非I-125的疗效与经截面动脉化疗联合治疗梗阻性黄疸的不可切除肝细胞癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To compare the therapeutic effects of I-125 versus non-I-125 combined with transcatheter arterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) with obstructive jaundice.

机译：为了比较I-125与非I-125的治疗效果与经截管动脉化疗栓塞（TACE）与阻塞性黄疸治疗不可切除的肝细胞癌（HCC）。

著录项

来源
《Digestive Diseases and Sciences》 |2018年第2期|共8页
作者
Li Shuangxi; He Xuewen; Dang Lei; Xu Fangyu; Fang Jin; Li Fenqiang; Wang Wenhui;
展开▼
作者单位

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

Lanzhou Univ Affiliated Hosp 1 Lanzhou 730000 Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
Hepatocellular carcinoma; Obstructive jaundice; Percutaneous transhepatic biliary drainage; I-125 radioactive seeds; Transcatheter arterial chemoembolization;

机译：肝细胞癌;梗阻性黄疸;经皮肾上腺胆道引流;I-125放射性种子;经截面动脉化疗栓塞;

相似文献

外文文献
中文文献
专利

1. Efficacy of I-125 Versus Non-I-125 Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice [J] . Li Shuangxi, He Xuewen, Dang Lei, Digestive Diseases and Sciences . 2018,第2期

机译：I-125对非I-125的疗效与经截面动脉化疗联合治疗梗阻性黄疸的不可切除肝细胞癌
2. Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients: Efficacy and safety [J] . Song Liu, Guangsheng Zhao, Guangji Yu, Journal of Cancer Research and Therapeutics . 2020,第5期

机译：经截管动脉化疗联合低剂量阿皮因治疗老年患者不可切除的肝细胞癌：疗效和安全性
3. Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization [J] . ChoiJ., RyuJ.K., LeeS.H., Journal of palliative medicine . 2013,第9期

机译：胆道引流伴随后的经动脉化疗栓塞治疗无法切除的肝癌并发梗阻性黄疸
4. Lentinan combined radiofrequency ablation and transcatheter arterial chemoembolization for hepatocellular carcinoma [C] . Liang Minghui, Xia Liding 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：慢病毒结合射频消融联合经导管动脉化疗栓塞治疗肝细胞癌
5. Sesquiterpene drugs as potential treatment for hepatocellular carcinoma (HCC): Preclinical evaluation of parthenolide administered via transarterial chemoembolization in a rat HCC tumor model. [D] . Chen, Zheng. 2016

机译：倍半萜类药物可作为肝细胞癌（HCC）的潜在治疗方法：在大鼠HCC肿瘤模型中，通过经动脉化学栓塞术施用的小白菊内酯的临床前评估。
6. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma [O] . XUESONG YAO, DONG YAN, DEZHONG LIU, -1

机译：经导管动脉化疗栓塞联合索拉非尼治疗无法切除的肝细胞癌的疗效和不良反应
7. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma [O] . XUESONG YAO, DONG YAN, DEZHONG LIU, 2015

机译：转截管动脉化疗组合与索拉非尼治疗不可切除肝细胞癌的疗效和不良事件

Efficacy of I-125 Versus Non-I-125 Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice

摘要

著录项

相似文献

相关主题

期刊订阅